Dynamic Membranes for Enhancing Resources Recovery from Municipal Wastewater.

Membranes (Basel)

CALAGUA-Unidad Mixta UV-UPV, Departament d'Enginyeria Química, Universitat de València, 46100 Burjassot, Spain.

Published: February 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This paper studied the feasibility of using dynamic membranes (DMs) to treat municipal wastewater (MWW). Effluent from the primary settler of a full-scale wastewater treatment plant was treated using a flat 1 µm pore size open monofilament polyamide woven mesh as supporting material. Two supporting material layers were required to self-form a DM in the short-term (17 days of operation). Different strategies (increasing the filtration flux, increasing the concentration of operating solids and coagulant dosing) were used to enhance the required forming time and pollutant capture efficiency. Higher permeate flux and increased solids were shown to be ineffective while coagulant dosing showed improvements in both the required DM forming time and permeate quality. When coagulant was dosed (10 mg L) a DM forming time of 7 days and a permeate quality of total suspended solids, chemical oxygen demand, total nitrogen, total phosphorous and turbidity of 24 mg L, 58 mg L, 38.1 mg L, 1.2 mg L and 22 NTU, respectively, was achieved. Preliminary energy and economic balances determined that energy recoveries from 0.032 to 0.121 kWh per m of treated water at a cost between €0.002 to €0.003 per m of treated water can be obtained from the particulate material recovered in the DM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877044PMC
http://dx.doi.org/10.3390/membranes12020214DOI Listing

Publication Analysis

Top Keywords

forming time
12
dynamic membranes
8
municipal wastewater
8
supporting material
8
coagulant dosing
8
required forming
8
permeate quality
8
treated water
8
membranes enhancing
4
enhancing resources
4

Similar Publications

Conventional gelatin's gel-to-sol transition upon heating restricts its utility in biomedical applications that benefit from a gel state at physiological temperatures such as Pluronic F127 and poly(NIPAAm). Herein, we present "rev-Gelatin", a gelatin engineered with reverse thermo-responsive properties that undergoes a sol-to-gel transition as temperature rises from ambient to body temperature. Inspired by the phase dynamics of common materials like candy and ice cubes, whose surfaces soften or partially melt under warming, facilitating inter-object adhesion- rev-Gelatin leverages this concept to achieve fluidity at room temperature for easy injectability.

View Article and Find Full Text PDF

Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.

View Article and Find Full Text PDF

Introduction: Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with a lack of clinical switch studies, contribute to clinician uncertainty when transitioning between LAIs. This analysis employed a population pharmacokinetic (popPK) modeling approach to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once monthly (PP1m) to TV-46000, a long-acting subcutaneous formulation of risperidone, once monthly (q1m), with a secondary analysis of PP1m to TV-46000 every 2 months (q2m).

Methods: For PP1m and TV-46000, concentration-time profiles for paliperidone and TV-46000 total active moiety (TAM; risperidone + paliperidone) were simulated on the basis of published popPK models with virtual populations of 5000 patients.

View Article and Find Full Text PDF

Objective: This study evaluated the outcomes of a 36-month follow-up after treatment with the ELLEX 2RT nanosecond laser.

Material And Methods: The study included 72 patients divided into two groups. Group 1 received 2RT nanosecond laser therapy, while group 2 did not undergo laser treatment.

View Article and Find Full Text PDF

Tuberculosis (TB) continues to cause significant global mortality, highlighting the need for improved drug delivery systems. The objective of this paper focuses in describing the formulation, optimization and in vivo assessment of rifampicin encapsulated PLGA microparticles for site-specific inhalation therapy. Microparticles for inhalation were produced by spray drying, and the DoE methodology was applied to reach the most suitable aerodynamic properties (mass median aerodynamics diameter (MMAD) 2.

View Article and Find Full Text PDF